Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C

[1]  A. Mondino,et al.  uPA and uPAR in fibrinolysis, immunity and pathology. , 2004, Trends in immunology.

[2]  M. Dewhirst,et al.  Circulating D‐dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma , 2004, Cancer.

[3]  Masao Tanaka,et al.  Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. , 2004, Anticancer research.

[4]  H. Kijima,et al.  [Histopathology and tumor markers]. , 2003, Rinsho byori. The Japanese journal of clinical pathology.

[5]  F. Blasi,et al.  The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy , 2003, Cancer and Metastasis Reviews.

[6]  P. Russell,et al.  Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer , 2003, Journal of surgical oncology.

[7]  M. Oya,et al.  High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. , 2001, Japanese journal of clinical oncology.

[8]  J. Jeekel,et al.  Effect of inflammatory cytokines and growth factors on tumour cell adhesion to the peritoneum , 2001, The Journal of pathology.

[9]  H. Nielsen,et al.  Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer , 2000, Annals of surgical oncology.

[10]  D. O’Toole,et al.  Activated protein C inhibits lipopolysaccharide‐induced nuclear translocation of nuclear factor κB (NF‐κB) and tumour necrosis factor α (TNF‐α) production in the THP‐1 monocytic cell line , 2000, British journal of haematology.

[11]  Tatsuo Tanaka,et al.  Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size , 1999, Cancer.

[12]  H. Allgayer,et al.  Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. , 1997, Cancer research.

[13]  E. Kruithof,et al.  Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells. , 1996, British Journal of Cancer.

[14]  A. Aasen,et al.  Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. , 1995, Human pathology.

[15]  H. Allgayer,et al.  Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer , 1995, Nature Medicine.

[16]  G. Schlimok,et al.  Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients , 1992, The Lancet.

[17]  B. Veingerl.  Serum carcinoembryonic antigen levels in patients operated for colorectal carcinoma. , 2001, Wiener Klinische Wochenschrift.

[18]  J. Helterbrand,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis , 2003 .

[19]  H. Kobayashi,et al.  Role of activated protein C in facilitating basement membrane invasion by tumor cells. , 1994, Cancer research.

[20]  S. D. Weston,et al.  Osseous metastasis from cancer of the colon, with a review of the literature , 1966, Diseases of the colon and rectum.